Detection and Characterization of a Novel Subset of CD8+CD57+ T Cells in Metastatic Melanoma with an Incompletely Differentiated Phenotype
Open Access
- 30 April 2012
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 18 (9), 2465-2477
- https://doi.org/10.1158/1078-0432.ccr-11-2034
Abstract
Purpose: Tumor‐specific T cells are frequently induced naturally in melanoma patients and infiltrate tumors. It is enigmatic why these patients fail to experience tumor regression. Given that CD8+ T cells mediate antigen‐specific killing of tumor cells, the focus of this study was to identify alterations in the differentiation of CD8+ residing at the tumor site, with emphasis on a population expressing CD57, a marker for terminal differentiation. Experimental Design: We conducted flow cytometric analysis of CD8+ tumor‐infiltrating lymphocytes (TIL) isolated from 44 resected melanoma metastases with known T‐cell differentiation markers. For comparison, peripheral blood mononuclear cells were isolated from matched melanoma patients. We sorted different CD8+ subsets found in TIL and determined their effector functions. In addition, we carried out Vβ clonotype expression analysis of T‐cell receptors to determine lineage relationship between the CD8+ TIL subsets. Results: The majority of CD8+ TIL was in the early-effector memory stage of differentiation. A significant population consisted of an oligoclonal subset of cells coexpressing CD27, CD28, CD57, and Granzyme B, with little or no perforin. These cells could be induced to proliferate, produce a high level of IFN-γ, and differentiate into CD27−CD57+, perforinhigh mature CTL in vitro. Addition of TGF‐β1 prevented further differentiation. Conclusions: Our studies identified a novel subset of incompletely differentiated CD8+ CTL coexpressing early effector memory and late CTL markers. This population resembles that found in patients with uncontrolled chronic viral infections. TGF-β1, frequently produced by melanoma tumors, may be a key cytokine inhibiting further maturation of this subset. Clin Cancer Res; 18(9); 2465–77. ©2012 AACR.Keywords
Other Versions
This publication has 54 references indexed in Scilit:
- CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subsetBlood, 2010
- Tumor-Reactive CD8+ Early Effector T Cells Identified at Tumor Site in Primary and Metastatic MelanomaCancer Research, 2010
- Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATFNature Medicine, 2010
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunityThe Journal of Experimental Medicine, 2010
- BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccinationJCI Insight, 2010
- Proliferation and interleukin 5 production by CD8hiCD57+ T cellsEuropean Journal of Immunology, 2008
- Heterogeneity and Cell-Fate Decisions in Effector and Memory CD8+ T Cell Differentiation during Viral InfectionImmunity, 2007
- Mechanisms of local immunosuppression in cutaneous melanomaBritish Journal of Cancer, 2007
- CD27 and CD57 Expression Reveals Atypical Differentiation of Human Immunodeficiency Virus Type 1-Specific Memory CD8 + T CellsClinical and Vaccine Immunology, 2007
- Mitogens, superantigens, and nominal antigens elicit distinctive patterns of TCRB CDR3 diversityHuman Immunology, 1996